CDX
BxPC-3
Tumor indication
Pancreatic
Tumor subtype
Pancreatic Ductal Adenocarcinoma
Description
BxPC-3 (Pancreatic Cancer CDX Model)
The BxPC-3 pancreatic cancer cell line was derived from a primary adenocarcinoma of the pancreas. Unlike many PDAC models, it is KRAS wild-type, providing a distinct genetic background for research. BxPC-3 exhibits mutations in TP53 and SMAD4, common drivers of pancreatic cancer. Its unique profile makes it an important complement to KRAS-mutant models.
Key Features:
- Derived from pancreatic adenocarcinoma.
- KRAS wild-type; TP53 and SMAD4 mutated.
- Epithelial morphology with glandular features.
- Aggressive growth in xenografts.
Applications:
BxPC-3 is used in pancreatic cancer drug screening, particularly in KRAS-independent contexts. Researchers use it to study tumor biology and alternative therapeutic pathways. The model supports biomarker identification and targeted therapy development. Its distinct mutation profile broadens preclinical PDAC research options.
Details
- Tumor indication
- Pancreatic
- Tumor subtype
- Pancreatic Ductal Adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.